Introduction: Acne, a disease of pilosebaceous unit, is a common dermatologic disorder affecting about 80%-95% of people in both genders in adulthood. The available treatment options are conventional topical and/or oral medications, which are associated with adverse effects, partial response only, contraindications and reoccurrences. This necessitates the need for the introduction of novel treatment for improving acne lesions.
Objective: The aim of writing this review is to provide evidence-based information regarding safety and efficacy of PDT in treating acne lesions.
Method: The search term 'Acne and PDT' were entered into a search of the National Library of Medicine's PubMed Database. The search returned a total of 143 sources among which 36 studies pertaining to the use of PDT in acne are included in this review article.
Result: 36 clinical trials were selected among which 24 trials were performed to see the effect of PDT in acne whereas 12 trials compared the effect of PDT with light or laser alone therapy. Among 24 trials that used PDT only, 3 were clinical trials with control, 14 were clinical trials without control, 6 were randomized controlled trials (RCT) and 1 was retrospective study. On the basis of results of these trials, it is seen that PDT is safe and effective method of treatment for acne lesions. Studies have shown that PDT can control both inflammatory and non-inflammatory acne lesions and can improve all severity of lesions from mild to severe.
Conclusion: Photodynamic therapy (PDT) has been extensively studied and found to be effective treatment modality for acne lesions. However, more RCTs are needed to establish standard guidelines regarding concentrations and incubation period of photosensitizers and optimal parameters of light sources. Further studies are needed to guide future research and help dermatologist to choose PDT as an effective treatment modality for treating acne lesions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pdpdt.2016.04.005 | DOI Listing |
Arch Dermatol Res
December 2024
Faculty of Medicine, Department of Dermatology and Venereology, University of Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Acne vulgaris (AV) has been associated with Cutibacterium acnes (C. acnes) colonization in sebaceous follicles. However, recent studies have revealed the role of skin microbiome dysbiosis in acne pathogenesis.
View Article and Find Full Text PDFCurr Med Chem
December 2024
Department of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Introduction: This study aimed to investigate the impact of coronavirus disease 2019 (COVID-19) syndrome on various aspects of acne exacerbation. Additionally, we aimed to explore the risk factors for acne exacerbation after COVID-19 syndrome.
Method: A total of 211 subjects with acne were enrolled, and their key demographic characteristics and lifestyle factors were recorded.
Cureus
November 2024
Dermatology, Imperial Dermatology, Hollywood, USA.
Isotretinoin (13-cis-retinoic acid) is a well-established systemic treatment for moderate to severe acne vulgaris, renowned for its ability to target multiple contributors to acne pathogenesis. However, its therapeutic potential extends beyond conventional acne management. This case report highlights its efficacy in treating recalcitrant pustular dermatosis, a condition that proved resistant to standard therapies and posed significant diagnostic challenges.
View Article and Find Full Text PDFJ Cosmet Dermatol
December 2024
La Roche Posay Laboratoire Dermatologique, Levallois-Perret, France.
Background: Post-inflammatory hyperpigmentation (PIHP) predominantly affects patients with melanin-rich skin, significantly impacting them psychosocially due to more frequent and severe pigmentary changes. In this study, the efficacy of a novel depigmenting agent 2-mercaptonicotinoyl glycine (Melasyl) in a dermocosmetic (DC) serum formulation is assessed as a stand-alone treatment of PIHP without sunscreen.
Materials And Methods: Thirty-two Mauritian subjects aged 18-50 years of phototype IV-VI presenting mild acne (GEA2) and moderate to severe PIHP (PAHPI > 10) participated in this study.
Cureus
November 2024
Dermatology, Vivida Dermatology, Las Vegas, USA.
Acne vulgaris (AV) is a common dermatological condition that ranges from mild comedones to severe inflammatory nodules and scarring. Effective management is essential for improving patients' quality of life. The recent FDA approval of IDP-126 (Cabtreo™), a novel triple-combination gel, meets these needs by combining clindamycin phosphate, benzoyl peroxide, and adapalene into a single formulation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!